文献速递血栓与止血

重症监护室COVID-19患者的高凝状态:血栓弹力图表现及其他止血参数报告

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis.
PubMed 文献 · J Thromb Haemost · 2020-06-24

该研究对24例ICU的COVID-19患者行单次血栓弹力图检测(其中6例连续两日重复测量,共30次观察)并检测其他止血参数。结果显示TEG提示高凝状态,纤维蛋白原和D-二聚体升高,不符合急性DIC,支持高凝合并严重炎症状态,可解释静脉血栓栓塞事件并支持抗血栓预防/治疗。

要点

  • ICU的COVID-19患者TEG提示高凝状态,而非急性DIC。
  • 纤维蛋白原和D-二聚体升高,血小板正常或升高,PT和APTT接近正常。
  • 结果支持抗血栓预防/治疗,但药物类型、剂量和疗程需临床试验确定。

核心结论

  • ICU的COVID-19患者止血参数不符合急性DIC,而是支持高凝状态合并严重炎症状态。
  • 这些发现可能解释部分患者观察到的静脉血栓栓塞事件,并支持抗血栓预防/治疗。
  • 亟需临床试验确定预防药物的类型、剂量和最佳疗程。

研究设计与样本

  • 收集24例因COVID-19入住ICU患者的全血,使用TEG即时检测设备单次评估,其中6例连续两日重复测量,共30次观察。
  • 同时检测血浆其他止血参数。

主要发现

  • TEG参数符合高凝状态,表现为K值降低、K角和MA升高。
  • 血小板计数正常或升高,凝血酶原时间和活化部分凝血活酶时间接近正常。
  • 纤维蛋白原升高,D-二聚体显著升高,C反应蛋白升高。
  • 因子VIII和血管性血友病因子(n=11)升高;抗凝血酶(n=11)边缘性降低,蛋白C(n=11)升高。

临床怎么用

  • 对于ICU的COVID-19患者,应认识到高凝状态而非急性DIC,考虑抗血栓预防/治疗。
  • 抗血栓预防/治疗的具体药物、剂量和疗程需等待临床试验确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The severe inflammatory state secondary to COVID-19 leads to a severe derangement of hemostasis that has been recently described as a state of disseminated intravascular coagulation (DIC) and consumption coagulopathy, defined as decreased platelet count, increased fibrin(ogen) degradation products such as D-dimer, as well as low fibrinogen. AIMS: Whole blood from 24 patients admitted at the intensive care unit because of COVID-19 was collected and evaluated with thromboelastography by the TEG point-of-care device on a single occasion and six underwent repeated measurements on two consecutive days for a total of 30 observations. Plasma was evaluated for the other parameters of hemostasis. RESULTS: TEG parameters are consistent with a state of hypercoagulability as shown by decreased values, and increased values of K angle and MA. Platelet count was normal or increased, prothrombin time and activated partial thromboplastin time were near(normal). Fibrinogen was increased and D-dimer was dramatically increased. C-reactive protein was increased. Factor VIII and von Willebrand factor (n = 11) were increased. Antithrombin (n = 11) was marginally decreased and protein C (n = 11) was increased. CONCLUSION: The results of this cohort of patients with COVID-19 are not consistent with acute DIC, rather they support hypercoagulability together with a severe inflammatory state. These findings may explain the events of venous thromboembolism observed in some of these patients and support antithrombotic prophylaxis/treatment. Clinical trials are urgently needed to establish the type of drug, dosage, and optimal duration of prophylaxis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020. PMID: 32302438. doi:10.1111/jth.14850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。